Open Access. Powered by Scholars. Published by Universities.®
- Discipline
Articles 1 - 3 of 3
Full-Text Articles in Medicine and Health Sciences
Burning Pain Secondary To Clozapine Use: A Case Report., Bradley Linton, Rachel Fu, Penny A Macdonald, Hooman Ganjavi
Burning Pain Secondary To Clozapine Use: A Case Report., Bradley Linton, Rachel Fu, Penny A Macdonald, Hooman Ganjavi
Brain and Mind Institute Researchers' Publications
BACKGROUND: The first of the atypical antipsychotics introduced in the 1970s, clozapine remains the most efficacious neuroleptic to this day. However, serious and potentially fatal side effects have necessitated careful regular monitoring among prescribing clinicians. Some adverse effects (e.g. ischaemic bowel) remain under recognized, while newly identified adverse effects continue to be described in the literature.
CASE PRESENTATION: In this report, we describe a healthy 43-year old Caucasian male who experienced onset of a full body deep burning pain several months after the onset of treatment with clozapine. The pain worsened over time, ceased with cessation of treatment, and returned …
False Negative Studies May Systematically Contaminate The Literature On The Effects Of Inducers In Neuropsychopharmacology. Part Ii: Focus On Bipolar Disorder, Jose De Leon
Psychiatry Faculty Publications
No abstract provided.
Adult Response To Olanzapine Or Clozapine Treatment Is Altered By Adolescent Antipsychotic Exposure: A Preclinical Test In The Phencyclidine Hyperlocomotion Model, Qing Shu, Gang Hu, Ming Li
Adult Response To Olanzapine Or Clozapine Treatment Is Altered By Adolescent Antipsychotic Exposure: A Preclinical Test In The Phencyclidine Hyperlocomotion Model, Qing Shu, Gang Hu, Ming Li
Department of Psychology: Faculty Publications
This study examined how repeated olanzapine (OLZ) or clozapine (CLZ) treatment in adolescence alters sensitivity to the same drug in adulthood in the phencyclidine (PCP) hyperlocomotion model. Male adolescent Sprague-Dawley rats (postnatal day (P) 44–48) were first treated with OLZ (1.0 or 2.0 mg/kg, subcutaneously (sc)) or CLZ (10.0 or 20.0 mg/kg, sc) and tested in the PCP (3.2 mg/kg, sc)-induced hyperlocomotion model for five consecutive days. Then a challenge test with OLZ (0.5 mg/kg) or CLZ (5.0 mg/kg) was administered either during adolescence (~P 51) or after the rats matured into adults (~P 76 and 91). During adolescence, repeated …